cBioinformatics

Based in Japan, cBioinformatics Inc. focuses on precision cancer genome medicine, providing advanced genomic analysis software to enhance treatment efficacy tailored to individual patient characteristics. Founded in 2019 in Tokyo, Japan, cBioinformatics Inc. specializes in cancer genome analysis.

The company was established without any significant pivots or changes in operational strategy since its inception. There is no indication of the company being a subsidiary or having subsidiaries. The founder's history and prior ventures are not disclosed. As of March 31, 2026, the company raised an undisclosed amount in Series A funding, marking a total of 1 deal.

cBioinformatics specializes in the development of a comprehensive platform for cancer genome medicine, focusing on precision medicine tailored to individual patient characteristics. Its core offerings include proprietary integrated genomic analysis software capable of interpreting and analyzing genomic data, emphasizing the clinical and medical significance of findings. This platform enables healthcare providers to utilize molecular target drugs, enhancing cancer treatment protocols based on specific genetic profiles. The company's services have gained traction since the introduction of insurance coverage for necessary gene panel testing in June 2019, primarily serving hospitals, oncology clinics, and research institutions within Japan and extending to international markets.

cBioinformatics' revenue model is primarily based on partnerships with healthcare institutions and clinical laboratories utilizing its genomic analysis software and services for cancer treatment protocols. The company may engage in direct transactions with clients through subscription-based access to its software solutions, alongside potential consulting services for genomic data interpretation. Revenue may also arise from collaborations with research entities and pharmaceutical companies leveraging genomic insights for drug development and personalized medicine. The integrated genomic analysis platform meets the demand for precision medicine within the healthcare sector, facilitating improved patient outcomes through tailored treatment strategies.

In March 2026, cBioinformatics Inc. secured funding in Series A from new investor NS Solutions, which will be utilized to develop and commercialize a whole-genome cancer testing service by building the necessary IT and service platform. The company aims to expand its reach into new geographic markets, although specific regions have yet to be detailed. Upcoming products are in the design phase, with the whole-genome testing service expected to enhance their current offerings.